CONTINUOUS NEBULIZER TREATMENT Page 2 of 7 PROCEDURE FOR MASK DELIVERY
Check physician’s order. The continuous bronchodilator nebulization
therapy (CBNT) order should include treatment duration and total number of mg and/or cc to be delivered per hour. The physician’s order may also include a desired FIO2.
The CBNT must be reordered after the completion of the initial therapy.
Identify patient. Explain the purpose and procedure to the patient
The patient must be in a unit that will provide continuous cardiac and SPO2
monitoring such as ICU, SICU, ER or the Pediatric Unit. The availability of both O2 and AIR outlets may be necessary when precise oxygen concentrations are warranted.
Assess the patients HR, RR, WOB, SPO2, Breath Sounds, Color, Peak Flow,
Current O2 Device and ABG values, if available.
Remove the medication and saline from the storage area. Be sure to charge per
department policy for the correct amount of medication.
Prepare the medication and normal saline as noted under Section IV of this
policy. Pour medication and normal saline into reservoir.
Attach the oxygen supply tubing to the 50 psi wall outlet and/or oxygen tank and
regulator unit. Turn the flowmeter to the desired flow rate per manufactured specifications. Special Note: The EZflow (light blue reservoir) operates at 3 liters per minute. The EZflow MAX (dark blue reservoir) operates at 6 and 10 liters per minute flow. This is important in order to determine the nebulizer output (mist produced) over a one hour period of time.
Place mask snugly, not tightly, onto the patient’s face. Monitor the patient
closely for several minutes of CBNT. Certain variables may affect nebulizer function, such as wall outlet pressure and potential flowmeter inaccuracies. Check the nebulizer output and titrate accordingly. Assess the patient every 30 minutes initially, then every hour for the duration of the therapy. The assessment should include HR, RR, WOB, SPO2, breath sounds and peak flow. CONTINUOUS NEBULIZER TREATMENT Page 3 of 7
The nebulizer output for the EZflow (low flow, light blue reservoir) is 6 ml per
hour @ 3 liters per minute flow. The nebulizer output for the EZflow MAX (high flow, dark blue reservoir) is 12 ml @ 6 liters per minute flow and 16 ml @ 10 liter per minute flow. The medication reservoir capacity for both high and low flow systems is 24 ml. Therefore, the low flow system can nebulize up to 4 hours continuously, the high flow up to 1-1/2 hours at 10 liters per minute.
Chart the CBNT in accordance with the Respiratory Care Department policy.
The equipment used for the CBNT is single patient use and should be discarded
after use. Change the EZflow nebulizer after 48 hours of use. When a precise oxygen concentration is required, utilize a properly calibrated blender. ADVERSE REACTIONS
Stop the CBNT if adverse reactions occur. Return patient to previous O2 device.
Remain with the patient until adverse symptoms subside. Notify the physician immediately. Adverse reactions may be any of the following:
MEDICATION CALCULATION
The preparation and calculation in this protocol applies to Albuterol. The use of anyother bronchodilator in place of or with Albuterol must be reviewed by the physician. Recommended Albuterol Dosage: Calculations:
Albuterol - .5% Solution (5mg = 1ml, 10mg = 2ml, 15mg = 3ml, 20mg = 4ml)
CONTINUOUS NEBULIZER TREATMENT PAGE 4 OF 7
Mg/Hr of medication ordered divided by 5 equals the ml of medication used
Note the nebulizer’s output (amount of mist produced per hour) per manufacturer
specifications. EZflow - Low Flow (light blue reservoir) is 6 ml operating at 3 liters per minute flow. The EZflow MAX - High Flow (dark blue reservoir) output is 12 ml operating at 6 liters per minute flow and 16 ml at 10 liters per minute flow. Follow this equation for a one (1) hour treatment: (Output of nebulizer) - (ml of medication ordered) = ml of Normal Saline to add
If multiple hours of therapy is ordered by the physician, multiply both the
medication ordered in ml and the saline diluent in ml times the number of hours desired. EZflow - Low Flow (Light Blue Reservoir) Output 6cc @ 3 lpm flow DOSING REFERENCE 5 mg (1 cc/Hr) Output @ 3 lpm Albuterol in cc’s Saline Mixture 10 mg (2 cc/Hr) Output @ 3 lpm Albuterol in cc’s Saline Mixture CONTINUOUS NEBULIZATION TREATMENT Page 5 of 7 15 mg (3 cc/Hr) Output @ 3 lpm Albuterol in cc’s Saline Mixture 20 mg (4 cc/Hr) Output @ 3 lpm Albuterol in cc’s Saline Mixture EZflow MAX - High Flow (Dark Blue Reservoir) 6 Liters per Minute flow DOSING REFERENCE 5 mg (1 cc/Hr) Output @ 6 lpm Albuterol in cc’s Saline Mixture CONTINUOUS NEBULIZATION TREATMENT Page 6 of 7 10 mg (2 cc/Hr) Output @ 6 lpm Albuterol in cc’s Saline Mixture 15 mg (3 cc/Hr) Output @ 6 lpm Albuterol in cc’s Saline Mixture 20 mg (4cc/Hr) Output @ 6 lpm Albuterol in cc’s Saline Mixture EZflow MAX - High Flow (Dark Blue Reservoir) 10 Liters per Minute flow DOSING REFERENCE 5 mg (1 cc/hr) Output @ 10 lpm Albuterol in cc’s Saline Mixture 10 mg (2 cc/hr) Output @ 10 lpm Albuterol in cc’s Saline Mixture CONTINUOUS NEBULIZATION TREATMENT Page 7 of 7 15 mg (3 cc/hr) Output @ 10 lpm Albuterol in cc’s Saline Mixture 20 mg (4 cc/hr) Output @ 10 lpm Albuterol in cc’s Saline Mixture TREATMENT COMPLICATIONS
Failure may include, but is not limited to the following:
Failure to significantly respond in 8 hours.
Decreasing aeration over time or increased wheezing without asimultaneous increase in aeration.
Decreasing pulse oximeter readings or an increasing need for higherFiO2’s to maintain the same saturation.
Decreased level of consciousness or decreased ability to awaken the patient.
Anything that leads you to believe, through your assessment,that the patient is getting worse.
Be aware that there can be a decrease in electrolyte levels, specifically Potassium (K+). Patients receiving beta agonists may benefit fromhaving their electrolyte levels periodically evaluated by a physician.
When treatment failure is suspected, re-evaluate the patient and contactthe physician immediately.
A weekly update of long-term care news and information for ASHS members. FRIDAY, NOVEMBER 08, 2013 HEADLINES J&J pays out billions for promoting off-label use of Risperdal, other drugs Johnson & Johnson settled with the Justice Department for more than $2.2 billion earlier this week. The settlement is the result of accusations that J&J marketed the drug Risperdal for off-la
L'ITALIA ADOTTA LA PASTICCA 'CALMA BAMBINI' A proposito di RITALIN - AGGIORNAMENTO SUI FARMACI La FDA americana autorizza la somministrazione del Prozac ai bambini oltre i sei anni d'età? Il Ministero della Salute guidato da Girolamo Sirchia si appresta a fare altrettanto con il Ritalin. E' ormai pronto per la firma il decreto che autorizza la commercializzazione in Italia del tanto dis